Starpharma to advance with phase III studies for VivaGel
Wednesday, 11 January, 2012
Starpharma has kicked off the year with a tick from the US Food and Drug Administration for its study design for phase III trials of VivaGel under the FDA’s Special Protocol Assessment scheme.
The agreement with the FDA confirms that the study design, endpoints, statistical analyses and other aspects of the trial are acceptable for achieving regulatory approval.
The company intends to undertake two phase III trials of VivaGen for the treatment of bacterial vaginosis (BV) this year, with results anticipated before the year’s end.
Assuming positive results, the company intends to partner in order to progress to marketing stage.
“Following our recent financing, we are also implementing various initiatives in collaboration with our CRO to expedite the trial timelines as much as possible,” said Dr Jackie Fairley, Chief Executive Officer of Starpharma.
Starpharma’s (ASX:SPL) is steady at $1.20.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
